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Abstract
Background: To compare clinical and health-related quality of life (HRQoL) outcomes between children and
adolescents with ADHD treated with OROS
® MPH, using data from two large similarly-designed multicenter,
prospective, open-label, single-arm, non-interventional studies.
Methods: Pooled analysis (42603ATT4037, 42603 - ATT - 4001) including patients (6 to 18 years) with a confirmed
diagnosis of ADHD. Patients were treated with OROS
® MPH for 12 weeks; ADHD symptoms, functioning, HRQoL,
safety and tolerability parameters were assessed.
Results: 822 patients (583 children [6-12 years], 239 adolescents [13-18 years]) were included in the pooled
analysis. Mean daily OROS
® MPH starting doses in the child and adolescent subgroups were 29.0 ± 11.7 and 37.6 ±
15.6 mg, respectively (p < 0.001). At study end (week 12), the overall mean daily dose was 35.5 ± 14.0 mg, with
children and adolescents receiving 32.8 ± 12.7 and 42.0 ± 15.1 mg/day, respectively (p < 0.001). Significant (p <
0.0001: overall population, children, adolescents) symptomatic, functional and HRQoL improvements were observed
from baseline to study end using the Conners’ Parents Rating Scale (overall: 29.2 ± 10.7 [baseline] to 19.3 ± 11.3
[endpoint]), Children’s Global Assessment Scale (overall: 58.5 ± 14.5 [baseline] to 69.6 ± 16.1 [endpoint]), and ILC-
LQ0-28. At week 12, between-age group differences were seen in the individual ILC-LQ0-28 parameters: school
performance (p = 0.001 [parents’ assessment], p = 0.032 [childrens’ assessment]), global QoL (p = 0.012 [parents’])
and interests and hobbies (p = 0.023 [childrens’]). Treating physician’s planned continued use of OROS
® MPH in
76.9%, 86.0% and 79.3% of children, adolescents and the total population, respectively, at study end (p = 0.029
between-age subgroups). 195 of 822 patients (23.7%) experienced at least one treatment-emergent adverse event;
most commonly reported AEs in the total group (≥4%) were insomnia (7.2%), anorexia (4.3%) and involuntary
muscle contractions (4.1%). No clinically relevant changes in body weight or vital signs were observed.
Conclusions: Clinically relevant differences between children and adolescents with ADHD are present. Adolescents
appeared to have a lower health related quality of life and functioning compared to children at baseline, however,
they were able to reach comparable ratings at endpoint for most items. Similarly, burden of disease decreased in
patients and their carers. OROS MPH was generally safe and well tolerated.
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The effects of ADHD in children are well-documented,
impacting negatively on the child, peer group interac-
tion, immediate family and home life as well as on the
child’s educational performance at school [1,2]. Children
with ADHD often require special school education sup-
port services to aid their impaired learning [2,3].
Whilst an age-related decline in ADHD symptoms
occurs throughout childhood [4], it is evident that
ADHD persists into older age in the majority of indivi-
duals where it is associated with a range of clinical and
psychosocial impairments [5]. Numerous follow-up stu-
dies of children with ADHD show that the disorder per-
sists during adolescence and adulthood in around two-
thirds of individuals with persistence of symptoms asso-
ciated with continued clinical and psychosocial impair-
ments [5]. A detailed longitudinal study of remission in
boys with ADHD showed that syndromatic remission
occurred in 60%, although most continued to experience
ADHD symptoms (particularly inattention) and dysfunc-
tion after the age of 20 years [4]. Compared with healthy
adolescents, fewer adolescents with ADHD enroll in col-
lege [2] and significantly higher absenteeism rates are
observed [3]. Combined with continued learning disabil-
ities, adolescents with ADHD also demonstrate impaired
interpersonal relationships at school/college and at
home, have significantly fewer close friends, more pro-
blems maintaining friendships, increased antisocial beha-
vioural problems, greater parent-child conflict and
parental hostility, and considerable overall negative
impact as they progress into adulthood [1,2].
Whilst there may be differences between individuals in
some ADHD domains, the continuing overall impact of
childhood ADHD through adolescence appears to affect
both genders to a similar extent. Owens et al. [6]
recently demonstrated that very few girls diagnosed with
childhood ADHD showed positive adjustment across
multiple domains during adolescence, and concluded
that the negative consequences of childhood ADHD for
adolescent girls were equivalent to those reported in a
separate, primarily male ADHD population [7].
Methylphenidate (MPH) is a well-established and
recognized first-line stimulant treatment for children
and adolescents with ADHD, decreasing symptom fre-
quency and/or severity and improving functioning
[8-10]. Immediate-release (IR) and extended-release (ER)
MPH preparations are available, but these short-acting
formulations have a number of potential limitations,
including inconvenient multiple daily dosing that
requires in-school/college administration and associated
social attitudes and pressures, storage and handling pro-
blems [11], potential misuse and non-adherence leading
to suboptimal treatment efficacy [12]. Osmotic,
controlled-release (OROS) MPH, a long-acting MPH
formulation, uses OROS
® (osmotic release oral system)
technology to produce an ascending MPH plasma pro-
file [13]. In clinical trials, once-daily OROS MPH has
been shown to produce an extended duration of ADHD
symptom control, consistent with an up to 12-hour
duration of action [14-16].
The impact of health-related quality of life (HRQoL) is
well-established [17,18] and it has been noted that
HRQoL is not only lower in children and adolescents
with ADHD when compared to healthy age- and sex-
matched controls, but even when compared to children
with other chronic diseases, including asthma [19].
However, there are currently limited data on HRQoL,
everday functioning and well-being in children/adoles-
cents with ADHD [17,20] and even less information
documenting ‘real world’ changes in these parameters in
patients with ADHD treated with MPH, or switching to
OROS MPH.
This pooled analysis of two similarly-designed multi-
center, prospective, open-label, single-arm, non-inter-
ventional studies [8-10], primarily explores differences
with regard to effectiveness, tolerability and changes in
HRQoL of OROS MPH between children and adoles-
cents with ADHD [ICD-10 criteria (hyperkinetic disor-
ders)] in a large cohort.
Methods
Study design and participants
This pooled analysis combines data from two similarly-
designed large multicenter, prospective, open-label, sin-
gle-arm, non-interventional studies (the LeCO study [8]
and the GER-CON-2 study [9,10], 42603ATT4037,
42603 - ATT - 4001) which explored the efficacy, safety,
tolerability and HRQoL outcomes of children and ado-
lescents with ADHD treated with individualised dosing
of OROS
® MPH (Concerta
®; Janssen Cilag GmbH, Ger-
many) over a 12-week treatment period. Patients had
been treated with either atomoxetine, extended-release
(ER) methylphenidate (GER-CON-2), or any ADHD-
relevant psychostimulant (LeCO), before they started on
OROS MPH. The pooled analysis specifically evaluated
data in distinct age subgroups in order to explore poten-
tial differences in outcomes between children (aged 6-12
years) and adolescents (aged 13-18 years) with ADHD.
The two studies were conducted in paediatric, paedia-
tric neurology, child and adolescent medicine practices
or by child and adolescent psychiatrists. OROS
® MPH
was prescribed according to its summary of product
characteristics (SmPC). Starting and final dosages, as
well as titration rates, were based on therapeutic effec-
tiveness. Each study comprised five visits: baseline (week
0), brief follow-up visits after 1, 3 and 6 weeks of
Berek et al. Child and Adolescent Psychiatry and Mental Health 2011, 5:26
http://www.capmh.com/content/5/1/26
Page 2 of 13OROS
® MPH treatment, as well as a final visit after 12
weeks, or upon premature termination (study end).
Children and adolescents aged 6-18 years who had a
confirmed diagnosis of ADHD (any subtype) by ICD-10
(F90.x: hyperkinetic disorders or F98.8) criteria, and in
whom treatment with OROS
® MPH was medically indi-
cated and planned by the treating physician, were eligi-
ble to participate in the studies. In the GER-CON-2
study, patients should have been pretreated with ato-
moxetine (Strattera
®) or ER methylphenidate (Mediki-
net
® retard); in the LeCO study, patients should have
been pretreated with any ADHD-relevant psychostimu-
lant. Given the non-interventional design of the studies,
there were no specific exclusion criteria.
Ethics
An independent ethics committee (Freiburger Ethik-
Kommission GmbH international [feki], Freiburg, Ger-
many) reviewed and approved the two clinical study
protocols, and consent was obtained from all partici-
pants and/or their care givers for data collection and
source data verification.
Symptomatic outcome measures
Symptomatic outcomes were assessed at week 0 (base-
line; at the start of OROS
® MPH treatment), week 6
and week 12 (or upon termination for individuals who
did not complete the study) using the Conners’ Parent
Rating Scale (CPRS) [21-23] which assesses symptoms
of ADHD and other psychopathology and problem
behaviour in children/adolescents aged 3-17 years. The
scale uses a 4-point Likert format (0 = never, rarely; 1 =
sometimes; 2 = frequently; 3 = very frequently and regu-
larly). The two studies employed a short-form 18-item
test with a total sum score ranging between 0 (best) to
54 (worst). A primary response was defined as a reduc-
tion in the total score of ≥30% and a secondary response
as a reduction in score of ≥ 20%. Parents were asked to
consider the patient’s behaviour during the previous
month.
Health-related quality of life and functionality measures
Functionality and HRQoL outcomes were assessed at
baseline and study end using the disease non-specific,
‘Inventory for Assessment of Quality of Life in Children
and Adolescents’ (ILC [24-28]) which is a short ques-
tionnaire that takes approximately 5-15 minutes to com-
plete. The German version of the ILC which was used in
the two studies has been validated by Mattejat and
Remschmidt [29]. After two independent forward, and
one backward, translations, a Norwegian version of the
ILC was investigated by Jozefiak and colleagues [28] in a
Norwegian sample of 1997 school children aged 8-16
years and their parents. The ILC measures HRQoL over
the past week and is sensitive to therapeutic interven-
tions and changes in well-being over time.
Items 1-7: There are 7 core items of the ILC for nor-
mal children and patients, respectively, and their par-
ents, consisting of: (1) school performance, (2) family
functioning, (3) social integration, (4) interests and hob-
bies, (5) physical health, (6) emotional and physical well-
being, and (7) global HRQoL ("overall”).
Items 8-9: There are 2 additional items for the
patients and their parents/caregivers: (8) problems (bur-
den of present disorder/disease) and (9) overall evalua-
tion of therapy (burden associated with the overall
evaluation/diagnostic procedures and therapy).
Items 10-11: Additionally, there are 2 items for par-
ents/caregivers of patients only: (10) problems (burden
of present disorder/disease for parents/caregivers) and
(11) overall evaluation of therapy (burden associated
with the overall evaluation/diagnostic procedures and
therapy for parents/caregivers).
All items on the ILC are rated on 5-point Likert scales
(items 1-7: 1 = very good, 2 = rather good, 3 = mixed, 4
= rather bad, 5 = very bad; items 8-11: 1 = no problem,
2 = minor problem, 3 = moderate problem, 4 = signifi-
cant problem, 5 = very significant problem). For chil-
dren aged 6-11 years, the ILC is administered in a
structured interview; adolescents and parents/caregivers
complete the questionnaire on their own.
Three scores can be calculated from the 7 core items
(items 1-7). For the purpose of this analysis, the overall
score termed ‘LQ0-28’ was calculated if at least 4 of the
7 core items were answered. The LQ0-28 score ranges
from 0 (worst) to 28 (best) and is calculated as LQ0-28:
= ROUND[ABS(S*7/N-35)] where N and S are the num-
ber and sum of answered items, respectively, and ABS
and ROUND the absolute and rounding function. Thus,
scoring all 7 core items with 1 = ‘very good’ results in a
LQ0-28 score of ROUND[ABS(7*1*7/7-35)] = ROUND
[ABS(7-35)] = ROUND[ABS(-28)] = 28, scoring all 7
core items with 5 = very bad results in a LQ0-28 score
of ROUND[ABS(7*5*7/7-35)] = ROUND[ABS(0)] = 0.
In the absence of a control group (healthy or placebo)
in the two studies involved in this pooled analysis, data
from Professor Mattejat’s ILC-validation samples [29]
were used for comparison: (1) data from 9418 ILC ques-
tionnaires completed by healthy children/adolescents
and (2) data from 1140 ILC questionnaires completed
by the parents of other healthy youngsters. From the
validation samples, two samples matching the gender
and age of the study group discussed in this paper were
drawn. Validation sample data are based on a one-time
evaluation.
The Children’s Global Assessment Scale (C-GAS) is
an instrument developed by Shaffer and colleagues to
provide a global measure of the level of functioning in
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gle global rating on a scale of 0 (worst) to 100 (best).
The C-GAS was employed by the treating physician,
based on information from an interview with the par-
ents, at baseline (week 0) and weeks 6 and 12.
Other assessments
Problems concerning social interactions and tasks were
assessed via several non-validated questions. At each of
the study visits, problems occurring in late afternoon (4
pm to 8 pm) that related specifically to ‘playing with
other children’, ‘household chores’, ‘school homework’,
‘going to bed’,a n d‘behaviour towards visitors/at visits’
were rated (’P l e a s ei n d i c a t ew h e t h e rt h ep r o b l e m s
occurred between 4 pm and 8 pm and, if they occurred,
how pronounced were they?) using a 4-point scale with
the categories being: 0 = none, 1 = mild, 2 = moderate
and 3 = severe.
Sleep quality (’How would you rate the sleep quality of
patients in the last week?’) and appetite (’How would
you rate the appetite of patients in the last week?) were
also assessed at each of the study visits, using a 5-point
rating scale with the categories being: ‘very good’, ‘good’,
‘satisfactory’, ‘sufficient’, and ‘insufficient’.
Safety and tolerability assessments
Tolerability parameters included documentation of
adverse events (AEs) throughout the two studies,
recording of vital signs (blood pressure and heart rate)
at all visits, and body weight at baseline and at the final
visit.
Data management and statistical analysis
All data were documented in Case Record Forms by the
treating physician, entered into the database using a
double data entry system and then checked for consis-
tency and completeness. AEs were coded according to
WHO Adverse Reaction Terminology.
Descriptive statistical estimators such as frequency
counts, arithmetic means ± SD (standard deviation),
median and range were used depending on the scale
level. Pre-post comparisons were performed using Wil-
coxon’s test for dependent samples. Differences between
children and adolescents, the primary topic of this
paper, were analyzed by means of the Chi
2-o rt h e
Mann-Whitney-U-test, respectively.
All tests were performed in a 2-sided manner in an
exploratory sense without adjustment for multiple
testing.
The evaluations were performed according to the
intention-to-treat (ITT) principle. All enrolled patients
who had received at least one dose of OROS
® MPH and
who had at least one follow-up effectiveness assessment
were available for the ITT-analysis of effectiveness data.
Effectiveness data were presented as changes from base-
line, missing values were imputed by the LOCF-method,
where appropriate. The safety group included all
patients who had at least one dose of OROS
® MPH and
had safety data reported.
Results
Baseline demographics and disease characteristics
This pooled analysis evaluated data from a total of 822
patients with ADHD; 598 patients were from the LeCO
study [8] and 224 patients were from the GER-CON-2
study [9,10]. Relevant baseline patient demographics and
disease characteristics are shown in Table 1. Of the 822
patients in the total ITT and safety analysis, there were
583 children (mean age 9.8 ± 1.6 years, range 6-12
years) and 239 adolescents (mean age 14.4 ± 1.3 years,
range 13-18 years), with 85% of all participants being
male. The overall mean age at first diagnosis of ADHD
was 8.1 ± 2.5 years and the average duration since diag-
nosis at study start was 2.4 ± 1.6 and 4.3 ± 2.7 years in
the children and adolescent subgroups, respectively
(between-group difference, p < 0.001). The mean dura-
tion of observation was 86.7 ± 28.5 days in the overall
ITT population. Approximately two-thirds of all patients
had a diagnosis of F90.0 (disturbance of activity and
attention).
Treatment with OROS MPH
Patients had been treated with atomoxetine, ER MPH or
IR MPH prior to study start. The mean daily starting
dose of OROS MPH was 29.0 ± 11.7 (median: 36 mg,
range: 18-72 mg) [children] and 37.6 ± 15.6 mg (med-
ian: 36 mg, range: 18 to 72 mg) [adolescents], respec-
tively (p < 0.001). At study end, the mean OROS MPH
daily dose had increased significantly (p < 0.001) to 32.8
± 12.7 and 42.0 ± 15.1 mg for children and adolescents,
respectively, with no between-group difference (p =
0.579) [Table 2]. Similarly, mean daily OROS MPH
doses, expressed in mg/kg bodyweight, were 0.9 ± 0.4
(median: 0.82 mg/kg/day) [children] and 0.7 ± 0.4 (med-
ian 0.66 mg/kg/day) [adolescents], respectively (p <
0.001). At study end, the mean OROS MPH daily dose
(by bodyweight) had increased significantly (p < 0.001)
for both children and adolescents from baseline, with no
between-group difference (p = 0.665) [Table 2].
Mean OROS MPH treatment duration was 83.0 ± 30.3
days (children) and 87.4 ± 27.2 days (adolescents)
(between-group difference, p = 0.012).
Conners’ Parent Rating Scale
The overall mean CPRS score improved from 29.2 ±
10.7 at baseline to 19.3 ± 11.3 at week 12 (endpoint) [p
< 0.0001; Figure 1]. Adolescents had slightly, but not
statistically significantly, better CPRS scores than
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baseline and week 12 (endpoint) were seen in children
(baseline: 29.7 ± 10.8, week 12: 19.9 ± 11.6, p < 0.0001)
and adolescents (baseline: 28.1 ± 10.1, week 12: 17.8 ±
10.4, p < 0.0001). However, improvements were not sig-
nificantly different between age groups (p = 0.279).
Children’s Global Assessment Scale
The mean C-GAS score for all patients improved from
58.5 ± 14.5 at baseline to 69.6 ± 16.1 at week 12 (p <
0.0001). As shown in Figure 2, significant improvements
between baseline and week 12 were recorded for chil-
dren (11.0 ± 14.1; p < 0.0001) and adolescents (11.2 ±
13.3; p < 0.0001), respectively. Improvements were not
significantly different between age groups (p = 0.402).
Inventory for assessing health-related quality of life (ILC)
The mean ILC LQ0-28 score for children improved sig-
nificantly from 17.2 ± 3.9 at baseline to 19.4 ± 4.0 at
endpoint (p < 0.0001) according to parents’ ratings, and
from 18.6 ± 4.1 to 20.6 ± 3.9 (p < 0.0001) according to
patients’ ratings. For adolescents, the mean ILC LQ0-28
Table 1 Demographic data and disease characteristics (by age group).
Age 6-12 years
N = 583
13-18 years
N = 239
All patients
N = 822
U-test
1
Chi
2-test
2
Gender, n (%) p = 0.460
2
Female 84 (14.41) 40 (16.74) 124 (15.09)
Male 499 (85.59) 199 (83.26) 698 (84.91)
Age at study start (years)
mean ± SD 9.75 ± 1.59 14.38 ± 1.29 11.10 ± 2.58 p < 0.001
1
minimum, median, maximum 6,10,12 13,14,18 6,11,18
Age at study start (years) by group, n (%)
6-9 251 (43.05) 0 (0.00) 251 (30.54)
10-12 332 (56.95) 0 (0.00) 332 (40.39)
13-15 0 (0.00) 197 (82.43) 197 (23.97)
16-18 0 (0.00) 42 (17.57) 42 (5.11)
Age at first diagnosis of disease (years) p < 0.001
1
valid N 565 220 785
mean ± SD 7.31 ± 1.85 9.97 ± 2.86 8.06 ± 2.49
minimum, median, maximum 2,7,12 1.0,10.0,16.0 1.0,8.0,16.0
Duration of disease at study start (years) p < 0.001
1
valid N 565 220 785
mean ± SD 2.41 ± 1.56 4.27 ± 2.71 2.93 ± 2.12
minimum, median, maximum 0.03,2.1,7.9 0.17,3.8,12 0.03,2.51, 12
Diagnosis of ADHD (ICD-10) n (%)
3
F90.0: disturbance of activity and attention 364 (62.44) 155 (64.85) 519 (63.14) p = 0.567
2
F90.1: hyperkinetic conduct disorder 227 (38.94) 89 (37.24) 316 (38.44) p = 0.707
2
F90.8: other hyperkinetic disorder 8 (1.37) 6 (2.51) 14 (1.70) p = 0.396
2
F90.9: hyperkinetic disorder, unspecified 18 (3.09) 3 (1.26) 21 (2.55) p = 0.205
2
others 41 (7.03) 24 (10.04) 65 (7.91) p = 0.287
2
Previous and/or concomitant diseases (ICD-10) n (%)
3
No 351 (60.21) 145 (60.67) 496 (60.34) p = 0.964
2
Others 47 (8.06) 26 (10.87) 73 (8.88)
F91.X: conduct disorder 134 (22.98) 53 (22.18) 187 (22.75) p = 0.288
2
F91: incl. F91.3 oppositional defiant disorder 103 (17.67) 37 (15.48) 140 (17.03) p = 0.512
2
F41: anxiety disorder 25 (4.29) 7 (2.93) 32 (3.89) p = 0.534
2
F42: obsessive-compulsive disorder 12 (2.06) 3 (1.26) 15 (1.82) p = 0.599
2
F1X: substance abuse 0 (0.00) 6 (2.51) 6 (0.73) p = 0.001
2
1,2 p-values from the corresponding test between age groups: 6-12 years and 13-18 years
3 multiple responses possible; Chi
2-test always yes vs. no
Berek et al. Child and Adolescent Psychiatry and Mental Health 2011, 5:26
http://www.capmh.com/content/5/1/26
Page 5 of 13score improved significantly from 16.4 ± 3.9 at baseline
to 19.1 ± 4.0 at study end (p < 0.0001) according to par-
ents’ r a t i n g s ,a n df r o m1 8 . 4±3 . 7t o2 0 . 4±3 . 6( p<
0.0001) according to patients’ ratings (Figure 3). Mean
baseline ILC LQ0-28 scores were significantly (p =
0.009) lower in the adolescent subgroup for parents’ rat-
ings although between-group differences at week 12
were not significantly different.
Mean baseline and study end (week 12) scores for each
individual ILC item are shown in Figure 4a (parents’
assessments) and Figure 4b (patients’ assessments), for
the overall population and the ‘children’ and ‘adolescents’
subgroups. At baseline, parents’ assessments showed sig-
nificant differences between children and adolescents in
family functioning (p = 0.001), mental health (p = 0.006)
and global QoL (p = 0.002). Patients’ assessments showed
significant between-age group differences at baseline in
school performance (p = 0.008), social integration (p =
0.006) and physical health (p = 0.014).
At study end, significant improvements from baseline
were observed in the overall patient population for all
individual items according to parents’ ratings (p = 0.03
for physical health and p < 0.001 for all other items).
Analysis of both age subgroups showed that improve-
ments in the ‘physical health’ item were not statistically
significant according to parents’ ratings (p = 0.12); all
other parameters were significantly improved (Figure
4a). According to patients’ ratings, all individual ILC
items improved significantly in both age subgroups and
in the overall population (Figure 4b). At study end,
between-age group differences were seen in school per-
formance (p = 0.001 [parents’ assessment], p = 0.032
[patients’ assessment]), global QoL (p = 0.012 [parents’])
and interests and hobbies (p = 0.023 [patients’]).
The additional ILC item regarding the patient’sb u r -
den associated with ADHD improved on average by
0.44 ± 1.11 (p < 0.0001) in the overall population when
assessed by the patients and by 0.65 ± 1.10 (p < 0.0001)
Table 2 Details of pre- and study medication.
Age 6-12 years
N = 583
13-18 years
N = 239
All patients
N = 822
U-test
2
Chi
2-test
3
Reason for starting OROS MPH, n (%)
1
N 142 (100.00) 82 (100.00) 224 (100.00) p < 0.090
3
insufficient effectiveness 92 (64.79) 63 (76.83) 155 (69.20)
adverse events 5 (3.52) 4 (4.88) 9 (4.02)
combination of both 45 (31.69) 15 (18.29) 60 (26.79)
Dose of OROS MPH
starting dose (mg/day) 29.05 ± 11.71 37.58 ± 15.62 31.53 ± 13.52 p < 0.001
2
minimum, median, maximum 18, 36, 72 18, 36, 108 18, 36, 108
last visit 32.82 ± 12.68 41.95 ± 15.07 35.47 ± 14.04 p < 0.001
2
minimum, median, maximum 18, 36, 72 18, 36, 108 18, 36, 108
Difference (mean ± SD) 3.77 ± 9.03 4.37 ± 10.43 3.94 ± 9.46 p = 0.579
2
Wilcoxon p-value < 0.0001 < 0.0001 < 0.0001
Dose of OROS MPH (mg/day/kg BW) N = 527
4 N = 223
4 N = 750
4
starting dose (mg/day/kg BW) 0.90 ± 0.41 0.73 ± 0.39 0.85 ± 0.41 p < 0.001
2
minimum, median, maximum 0.30,0.82,3.13 0.20,0.66,2.77 0.20,0.78,3.13
last visit 1.03 ± 0.45 0.82 ± 0.37 0.97 ± 0.44 p < 0.001
2
minimum, median, maximum 0.29,0.95,3.13 0.20,0.72,2.32 0.20,0.88,3.13
Difference (mean ± SD) 0.13 ± 0.32 0.08 ± 0.20 0.11 ± 0.29 p = 0.665
2
Wilcoxon p-value < 0.0001 < 0.0001 < 0.0001
Days of treatment with OROS MPH 82.90 ± 30.32 87.36 ± 27.15 84.20 ± 29.49 p = 0.012
2
Days of observation 85.97 ± 29.35 89.05 ± 26.10 86.87 ± 28.46 p = 0.046
2
Number (%) of patients with at least one additional application of IR MPH
between study start and study end
yes 180 (30.87) 68 (28.45) 248 (30.17) p = 0.546
3
no 403 (69.13) 171 (71.55) 574 (69.83)
1 Data only available for patients (n = 224) from the GER-CON-2 study
2,3 p-values from the corresponding test between age groups: 6-12 years and 13-18 years
4 Determined only in patients with bodyweight documented at first and last visit
Abbreviations: BW = bodyweight; IR = immediate-release; MPH = methylphenidate.
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ments in both age subgroups. For patients and parents,
this was the individual item with the largest mean
improvement. On average, the parents’ burden of dis-
ease improved from baseline to study end by 0.59 ±
1.03 (p < 0.0001) in the overall population. The burden
associated with diagnostic or therapeutic procedures
also improved significantly for parents and patients in
the overall population (p < 0.001).
The two individual ILC items with the worst baseline
scores in the analysis improved largely: item 1 (school
performance) and item 6 (mental health). These items
were only slightly worse or comparable to those of
healthy age-matched controls.
Other assessments
Based on data from 224 patients, at week 12, children
and adolescents showed significant (p ≤ 0.0001)
improvements from baseline in problems concerning
social interactions and tasks occurring in late afternoon
(4 pm to 8 pm) [Figure 5]. With the exception of a sig-
nificant baseline difference between children and adoles-
cents in the mean score for ‘household chores’ (p =
0.036) [no between-group difference at week 12 for this
parameter], no significant between-age group differences
were observed for any of the social interaction
parameters.
In the overall population (n = 822), quality of sleep (p
= 0.0034) and appetite (p = 0.0109) improved signifi-
cantly from baseline to study end. Sleep quality also
improved significantly from baseline in the adolescent
population (p = 0.0143). Significant between-age group
differences in sleep quality were observed at baseline (p
= 0.04) and study end (p = 0.002).
Overall, quality of sleep and appetite improved in
23.7% and 25.9% of patients, respectively, and worsened
in 32.5% and 32.4% of patients, respectively.
C o n t i n u e du s eo fO R O SM P Ha ts t u d ye n db yt h e
treating physician was planned in 76.9%, 86.0% and
79.3% of children, adolescents and the total population,
respectively. The difference between age subgroups
(children versus adolescents) was significant (p = 0.029).
Tolerability
In the overall population, 195 of the 822 patients
(23.7%) reported experiencing at least one AE causally
related to treatment (at least possible) during the study.
No significant difference (p = 0.066) in the incidence of
AEs were observed in children (25.6%) and adolescents
(19.3%). Overall, the study was prematurely terminated
due to AEs by 60 patients (7.3%), with 8.2% of children
and 5.0% of adolescents terminating the study due to
AEs (p = 0.144). The incidences of the most common
treatment-related AEs, and AEs as the reason for study
termination, are presented in Tables 3 and 4.
No serious AEs (SAEs; any adverse experience that
resulted in any of the following outcomes: death, a life-
threatening experience, inpatient hospitalization or pro-
longation of existing hospitalization [except inpatient
rehabilitation and inpatient hospitalisations planned
prior to the study], a persistent or significant disability/
incapacity, or a congenital anomaly/birth defect)
occurred that were considered to be causally related to
OROS
® MPH treatment.
Based on investigators’ assessments, the three most
commonly reported treatment-related AEs in the total
Figure 1 Mean Conners’ Parent Rating Scale (CPRS) scores:
overall (n = 822) and age subgroups. Data are presented for the
intention-to-treat analysis, last observation carried forward. Lower
scores denote improvement. Baseline to week 12 improvements
were p < 0.0001 for all groups (Wilcoxon test). Assessments at week
6 are only based on data from 224 patients.
Figure 2 Mean Children’s Global Assessment Scale (C-GAS)
scores. Data are presented for the overall population (n = 822) and
by age subgroups (intention-to-treat, last observation carried
forward). Higher scores denote improvement. Baseline to week 12
improvements were p < 0.0001 for all groups (Wilcoxon test).
Assessments at week 6 are only based on data from 224 patients.
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Page 7 of 13population, children (6-12 years) and adolescents (13-18
years) were insomnia (7.2%, 8.2% and 4.6% of patients,
respectively), anorexia (4.3%, 5.3% and 1.7%, respec-
tively) and involuntary muscle contractions (tics) [4.1%,
5.0% and 2.1%, respectively] (Table 3). Insomnia (2.3%,
2.7% and 1.3% of patients, respectively) and anorexia
(1.0%, 0.8% and 1.0%, respectively) were also the AEs
most commonly leading to premature termination
(Table 4) in the overall population, children and adoles-
cents, respectively).
Based on data from 598 patients, the overall tolerabil-
ity of OROS MPH was rated as ‘very good’ (37.8% and
34.8%) or ‘good’ (44.0% and 45.0%) by the majority of
physicians and parents, respectively. There was no sig-
nificant between-age group difference in the tolerability
of OROS MPH as rated by physicians (p = 0.065),
whereas the between-age group difference, as rated by
parents, was significant (p = 0.004).
On average, no clinically relevant weight changes, or
changes in vital signs, were observed during the study.
Discussion
This pooled analysis of over 800 children and adolescents
with ADHD shows that treatment with OROS MPH
improved symptomatic, functional and HRQoL measures
in a ‘real world’ setting. Significant improvements from
baseline (e.g. the start of OROS MPH treatment) were
observed with respect to symptoms, functioning and
HRQoL across both age categories (children and adoles-
cents) and for males and females, as reported by patients
and parents at week 12. Whilst differences between the
two age populations were not always statistically signifi-
cant for many of the evaluated parameters, significant
differences were observed in sleep quality and several
HRQoL parameters. Notably, at study end, between-age
group differences were seen in school performance (p =
0.001 [parents’ assessment], p = 0.032 [patients’ assess-
ment]), global QoL (p = 0.012 [parents’ assessment]) and
interests and hobbies (p = 0.023 [patients’ assessment]).
With the exception of ‘interests and hobbies’ (patients’
assessment), the greatest improvements in sleep quality
and these HRQoL parameters were observed in adoles-
cents. Given that ADHD persists beyond childhood into
older age where it is associated with a range of clinical
and psychosocial impairments [5], it is of interest that
our observations indicate that treatment with OROS
MPH is associated with even greater improvements in
several HRQoL parameters in adolescents compared with
children. Overall, similar findings were reported recently
from a pooled analysis of five clinical trials in which ato-
moxetine was generally shown to be effective in improv-
ing certain aspects of HRQoL in 794 children and
adolescents with ADHD [31].
In addition, in our study, all mean HRQoL values
were close to those reported for healthy controls after
12 weeks, although differences were not always statisti-
cally significant. OROS MPH was well tolerated, exhibit-
ing a safety profile in line with the SmPC.
Overall, the results from this ‘real world’ pooled analy-
sis align with data from controlled clinical studies that
Figure 3 Mean overall improvements in health-related quality of life (ILC-LQ0-28). Data are presented for the overall population and by
age subgroups (intention-to-treat, last observation carried forward). High scores denote high quality of life.
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Figure 4 Individual health-related quality of life (ILC) item scores assessed by (a) parents (P), and (b) patients (children/adolescents
[C]). Mean scores at baseline and at study end (week 12) [intention-to-treat, last observation carried forward]. Dx = diagnostic procedures. Tx =
therapeutic procedures. The right sides of the bars represent mean baseline values, the left sides mean values at week 12, the numbers mean
improvements between both time points.
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Page 9 of 13have evaluated treatment of children/adolescents with
ADHD with OROS MPH [14,32-34]. A 3-week UK and
German multicenter, open-label study showed that chil-
dren and adolescents (n = 105) with ADHD maintained
(teacher ratings) or had improved (parent/patient rat-
ings) symptom control after transitioning to OROS
MPH from IR MPH. The authors suggested that the
prolonged duration of action of OROS MPH improved
symptom control beyond the structured school day and
that increased improvements seen by parents/caregivers,
resulting from improved symptom control in the after-
school period, dominated the ratings [14]. Chou and
Figure 5 Mean scores for problems concerning social interactions and tasks occurring in late afternoon (4 pm to 8 pm). Data presented
for the overall population (n = 224) and children and adolescent subgroups (intention-to treat, last observation carried forward). At week 12, all
improvements from baseline were significant (p ≤ 0.0001).
Table 3 Adverse events causally related to treatment (at least possible) reported in at least 2% in any subgroup of
patients (sorted by percentages in the ‘All patients’ group).
Age 6-12 years
N = 583
13-18 years
N = 239
All patients
N = 822
Adverse event (AE)
[preferred term]
n% n %n %
Patients with at least one AE* 149 25.56 46 19.25 195 23.72
Insomnia 48 8.23 11 4.60 59 7.18
Anorexia 31 5.32 4 1.67 35 4.26
Muscle contractions involuntary 29 4.97 5 2.09 34 4.14
Medicine ineffective 13 2.23 5 2.09 18 2.19
Nervousness 13 2.23 4 1.67 17 2.07
Headache 10 1.72 5 2.09 15 1.82
Concentration impaired 7 1.20 7 2.93 14 1.70
Aggressive reaction 8 1.37 5 2.09 13 1.58
Abdominal pain 12 2.06 0 0.00 12 1.46
Weight decrease 4 0.69 6 2.51 10 1.22
* Chi2- Test: p = 0.066; some patients had more than one AE.
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Page 10 of 13colleagues [33] reported benefits in Taiwanese children
with ADHD (n = 137) who switched to OROS MPH
(for ≥ 3 weeks) after exhibiting consistently poor adher-
ence to at least 3 months’ treatment with IR MPH. Sig-
nificant improvements were noted in behavioural
symptoms and family/school measures. Improved neuro-
cognitive performance was also reported in an open-
label study involving Korean children (n = 102) with
ADHD who were switched from IR MPH to OROS
MPH for 28 days [34]. The clinical improvement with
OROS MPH seen in these studies probably relates to
improved compliance with a long-acting once-daily
medication and more consistent serum levels of MPH
achieved with the OROS formulation. Indeed, in a mul-
ticenter, double-blind, placebo-controlled crossover
study, Sonuga-Barke and colleagues showed that differ-
ences in the pharmacokinetic profiles of OROS
® MPH
(up to 12-hour duration of action) and a once-daily ER
MPH formulation (Metadate
®) resulted in predictably
different efficacy profiles over 12 hours in a classroom
setting of children with ADHD [32].
Further to clinical studies that have demonstrated the
successful transition from IR or ER MPH to OROS
MPH, several studies have shown the long-term benefits
of stimulant medication in children with ADHD. In a
population-based birth cohort, Barbaresi and colleagues
[35] have shown that stimulant treatment of 370
children with ADHD improved long-term school out-
comes, improving reading achievement, and decreasing
school absenteeism and grade retention. A longitudinal
case-control 10-year follow-up study recently provided
new evidence that stimulant treatment of children/ado-
lescents with ADHD may be protective against adverse
educational outcomes [36]. In this study, treatment with
stimulants significantly reduced the likelihood of disrup-
tive behaviour and recipients were less likely to repeat a
school/college grade than non-treated patients with
ADHD. In our study, children and adolescents with
ADHD were successfully treated with OROS MPH with
improvements in symptomatic, functional and HRQoL
measures; although patientsw e r eo n l yo b s e r v e df o r3
months, physician’s planned to continue longer-term
use of OROS MPH in 77% and 86% of children and
adolescents, respectively (p = 0.029 between-age sub-
groups). Furthermore, van den Ban and colleagues [37]
have recently shown that the use of long-acting OROS
MPH is associated with lower discontinuation rates in
patients with ADHD in the Netherlands, compared with
rates observed when only shorter-acting medications
were previously available.
This pooled analysis is not without some limitations.
Firstly, whilst the two contributing studies were of simi-
lar design, they were open-label and single arm, with no
control group. The overall population was restricted to
Table 4 Adverse events as reason for study termination reported in at least 1 patient in the total group (sorted by
percentages in the total group).
Age 6-12 years
N = 583
13-18 years
N = 239
All patients
N = 822
Adverse event (AE)
[preferred term]
n%n %n %
Patients with at least one AE* 48 8.23 12 5.02 60 7.30
Insomnia 16 2.74 3 1.26 19 2.31
Anorexia 6 1.03 2 0.84 8 0.97
Emotional lability 4 0.69 3 1.26 7 0.85
Muscle contractions involuntary 6 1.03 1 0.42 7 0.85
Depression 3 0.51 3 1.26 6 0.73
Abdominal pain 5 0.86 0 0.00 5 0.61
Aggressive reaction 4 0.69 1 0.42 5 0.61
Nervousness 4 0.69 1 0.42 5 0.61
Headache 1 0.17 3 1.26 4 0.49
Nausea 3 0.51 1 0.42 4 0.49
Apathy 1 0.17 2 0.84 3 0.36
Tachycardia 2 0.34 1 0.42 3 0.36
Anxiety 2 0.34 0 0.00 2 0.24
Concentration impaired 1 0.17 1 0.42 2 0.24
Dysphagia 2 0.34 0 0.00 2 0.24
Weight decrease 1 0.17 1 0.42 2 0.24
* Chi2- Test: p = 0.144; some patients had more than one AE.
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Page 11 of 13patients who were treated with OROS MPH and patient
motivation for study participation could have been
prompted by suboptimal efficacy, adverse events, and/or
low HRQoL with previous management strategies, possi-
bly contributing to a bias towards HRQoL improvement.
However, given the selection criteria, the pooled analysis
explores outcomes in a large and broad patient popula-
tion by including patients seen in ‘real world’ daily prac-
tice who may not participate in randomized controlled
trials. In addition, the relatively long study duration (12
weeks) may provide valuable information on longer
term treatment outcomes.
In conclusion, treatment with OROS MPH for 12
weeks in children and adolescents with ADHD was well
tolerated and was associated with improvements from
baseline in symptoms, functioning and HRQoL. Adoles-
cents appeared to have a lower health related quality of
life and functioning compared to children at baseline,
however, they were able to reach comparable ratings at
endpoint for most items. Furthermore, both parents and
affected individuals reported improved HRQoL and a
relevant decrease in burden of disease.
Acknowledgements
The authors thank patients, parents, physicians and allied health staff for
their participation.
Editorial assistance in the preparation of this manuscript was provided by
David P. Figgitt PhD, Content Ed Net; funding for this assistance was kindly
provided by Janssen-Cilag, GmbH, Neuss, Germany.
Author details
1Praxis für Kinder- und Jugendpsychiatrie, Eichenweg 73, D-30659 Hannover,
Germany.
2Klinik für Psychiatrie und Psychotherapie, Ratzeburger Allee 160,
D-23538 Lübeck, Germany.
3Janssen-Cilag Medical Affairs EMEA, Johnson &
Johnson Platz 5a, D-41470 Neuss, Germany.
4Klinik für Kinder- und
Jugendpsychiatrie und -psychotherapie am Universitätsklinikum Gießen und
Marburg, Standort Marburg, Hans-Sachs-Straße 4-6, D-35033 Marburg,
Germany.
5G.E.M. Gesellschaft für Evaluation und Qualitätssicherung in der
Medizin mbH, Meerbuscher Str. 47, D-40670 Meerbusch, Germany.
Authors’ contributions
All authors contributed equally to data analyses, interpretation, content
development and critical input. All authors read and approved the final
manuscript.
Competing interests
LH, LS and BS are employees of Janssen-Cilag, Germany. KR is a consultant
working for GEM, Meerbusch, Germany, who was hired and paid by Janssen-
Cilag to carry out the statistical analyses. MB, AK and FM declare no
competing interests.
Received: 6 May 2011 Accepted: 26 July 2011 Published: 26 July 2011
References
1. Wilens TE, Dodson W: A clinical perspective of attention-deficit/
hyperactivity disorder into adulthood. J Clin Psychiatry 2004, 65:1301-1313.
2. Barkley RA, Fischer M, Smallish L, Fletcher K: Young adult outcome of
hyperactive children: adaptive functioning in major life activities. JA m
Acad Child Adolesc Psychiatry 2006, 45:192-202.
3. Barbaresi WJ, Katusic SK, Colligan RC, Weaver AL, Jacobsen SJ: Long-term
school outcomes for children with attention-deficit/hyperactivity
disorder: a population-based perspective. J Dev Behav Pediatr 2007,
28(4):265-273.
4. Biederman J, Mick E, Faraone SV: Age-dependent decline of symptoms of
attention deficit hyperactivity disorder: impact of remission definition
and symptom type. Am J Psychiatry 2000, 157:816-818.
5. Kooij SJ, Bejerot S, Blackwell A, Caci H, Casas-Brugué M, Carpentier PJ,
Edvinsson D, Fayyad J, Foeken K, Fitzgerald M, Gaillac V, Ginsberg Y,
Henry C, Krause J, Lensing MB, Manor I, Niederhofer H, Nunes-Filipe C,
Ohlmeier MD, Oswald P, Pallanti S, Pehlivanidis A, Ramos-Quiroga JA,
Rastam M, Ryffel-Rawak D, Stes S, Asherson P: European consensus
statement on diagnosis and treatment of adult ADHD: The European
Network Adult ADHD. BMC Psychiatry 2010, 10:67.
6. Owens EB, Hinshaw SP, Lee SS, Lahey BB: Few girls with childhood
attention-deficit/hyperactivity disorder show positive adjustment during
adolescence. J Clin Child Adolesc Psychol 2009, 38(1):132-143.
7. Lee SS, Lahey BB, Owens EB, Hinshaw SP: Few preschool boys and girls
with ADHD are well adjusted during adolescence. J Abnorm Child Psychol
2008, 36:373-383.
8. Kordon A, Stollhoff K, Niederkirchner K, Mattejat F, Rettig K, Schäuble B:
Exploring the impact of once-daily OROS methylphenidate (MPH) on
symptoms and quality of life in children and adolescents with ADHD
transitioning from immediate-release MPH. Postgrad Med 2011.
9. Niederkirchner K, Slawik L, Wermelskirchen D, Rettig K, Schäuble B:
Transitioning to OROS methylphenidate from atomoxetine is effective in
children and adolescents with ADHD. Expert Rev Neurother 2011,
11(4):499-508.
10. Wolff C, Alfred A, Lindermüller A, Rettig K, Mattejat F, Gerwe M, Schäuble B:
Transitioning from extended-release methylphenidate (MPH) onto OROS
MPH improves symptoms, functionality and quality of life in children/
adolescents with ADHD: results of a 3-month non-interventional study.
Current Medical Research Opinion 2011.
11. Greenhill LL, Pliszka S, Dulcan MK, Bernet W, Arnold V, Beitchman J,
Benson RS, Bukstein O, Kinlan J, McClellan J, Rue D, Shaw JA, Stock S,
American Academy of Child and Adolescent Psychiatry: Practice parameter
for the use of stimulant medications in the treatment of children,
adolescents, and adults. J Am Acad Child Adolesc Psychiatry 2002, 41(2
Suppl):26S-49S.
12. Swanson J: Compliance with stimulants for attention-deficit/hyperactivity
disorder: issues and approaches for improvement. CNS Drugs 2003,
17:117-131.
13. Swanson J, Gupta S, Lam A, Shoulson I, Lerner M, Modi N, Lindemulde E,
Wigal S: Development of a new once-a-day formulation of
methylphenidate for the treatment of attention-deficit/hyperactivity
disorder: proof-of-concept and proof-of-product studies. Arch Gen
Psychiatry 2003, 60:204-211.
14. Remschmidt H, Hoare P, Ettrich C, Rothenberger A, Santosh P, Schmidt M,
Spender Q, Tamhne R, Thompson M, Tinline C, Trott GE, Medori R:
Symptom control in children and adolescents with attention-deficit/
hyperactivity disorder on switching from immediate-release MPH to
OROS® MPH. Results of a 3-week open-label study. Eur Child Adolesc
Psychiatry 2005, 14:297-304.
15. Coghill D, Seth S: Osmotic, controlled-release methylphenidate for the
treatment of ADHD. Expert Opin Pharmacother 2006, 7:2119-2139.
16. Wigal SB, Wigal T, Schuck S, Brams M, Williamson D, Armstrong RB, Starr HL:
Academic, behavioral, and cognitive effects of OROS® methylphenidate
on older children with attention-deficit/hyperactivity disorder. J Child
Adolesc Psychopharmacol 2011, 21:121-131, Epub 2011 Apr 13.
17. Coghill D, Soutullo C, d’Aubuisson C, Preuss U, Lindback T, Silverberg M,
Buitelaar J: Impact of attention-deficit/hyperactivity disorder on the
patient and family: results from a European survey. Child Adolesc
Psychiatry Ment Health 2008, 2:31.
18. Erhardt D, Hinshaw SP: Initial sociometric impressions of attention-deficit
hyperactivity disorder and comparison boys: predictions from social
behaviors and from nonbehavioral variables. J Consult Clin Psychol 1994,
62:833-842.
19. Escobar R, Soutullo CA, Hervas A, Gastaminza X, Polavieja P, Gilaberte I:
Worse quality of life for children with newly diagnosed attention-deficit/
hyperactivity disorder, compared with asthmatic and healthy children.
Pediatrics 2005, 116:e364-369.
20. Danckaerts M, Sonuga-Barke EJS, Banaschewski T, Buitelaar J, Döpfner M,
Hollis C, Santosh P, Rothenberger A, Sergeant J, Steinhausen H-C, Talor E,
Zuddas A, Coghill D: The quality of life of children with attention deficit/
hyperactivity disorder. Eur Child Adolesc Psychiatry 2010, 19:83-105.
Berek et al. Child and Adolescent Psychiatry and Mental Health 2011, 5:26
http://www.capmh.com/content/5/1/26
Page 12 of 1321. Conners CK: Rating scales in attention-deficit/hyperactivity disorder: use
in assessment and treatment monitoring. J Clin Psychiatry 1998, 59(suppl
7):24-30.
22. Conners CK: Clinical use of rating scales in diagnosis and treatment of
attention-deficit/hyperactivity disorder. Pediatr Clin North Am 1999,
46:857-870.
23. Conners CK, Sitarenios G, Parker JD, Epstein JN: The revised Conners’
parent rating scale (CPRS-R): factor structure, reliability, and criterion
validity. J Abnorm Child Psychol 1998, 26:257-268.
24. Mattejat F, Jungmann J, Meusers M, Moik C, Nölkel P, Schaff C, Scholz M,
Schmidt M-H, Remschmidt H: Das Inventar zur Erfassung der
Lebensqualität bei Kindern und Jugendlichen (ILK) - Eine Pilotstudie. Z
Kinder Jugendpsychiatr Psycother 1998, 26:174-182.
25. Mattejat F, Remschmidt H: Zur Erfassung der Lebensqualität bei
psychisch gestörten Kindern und Jugendlichen - Eine Übersicht.
[Assessing the quality of life of children and adolescents with
psychiatric disorders - an overview]. Z Kinder Jugendpsychiatr Psycother
1998, 26:183-196.
26. Mattejat F, Simon B, König U, Quaschner K, Barchewitz C, Felbel D,
Herpertz-Dahlmann B, Höhne D, Janthur B, Jungmann J, Katzenski B,
Naumann A, Nölkel P, Schaff C, Schulz E, Warnke A, Weinand F,
Remschmidt H: Lebensqualität bei psychisch kranken Kindern und
Jugendlichen. Z Kinder Jugendpsychiatr Psycother 2003, 31:293-303.
27. Ehnis P, Trosse M, Remschmidt H: Life quality of children and adolescents
in Germany. Results of a representative telephone survey [abstract]. In
16th World Congress of the International Association for Child and Adolescent
Psychiatry and Allied Professions: 22-26 August 2004. Edited by: Remschmidt
H, Belfer M. Steinkopf; 2004:374.
28. Jozefiak T, Larsson B, Wichstrøm L, Mattejat F, Ravens-Sieberer U: Quality of
life as reported by school children and their parents: a cross-sectional
survey. Health and Quality of Life Outcomes 2008, 6:34-45.
29. Mattejat F, Remschmidt H: Das Inventar zur Erfassung der Lebensqualität
bei Kindern und Jugendlichen (ILK) [The inventory of life quality in
children and adolescents (ILC)]. Verlag Hans Huber, Bern; 2006.
30. Shaffer D, Gould MS, Brasic J, Ambrosini P, Fisher P, Bird H, Aluwahlia S: A
children’s global assessment scale (CGAS). Arch Gen Psychiatry 1983,
40:1228-1231.
31. Wehmeier PM, Schacht A, Escobar R, Savill N, Harpin V: Differences
between children and adolescents in treatment response to
atomoxetine and the correlation between health-related quality of life
and Attention Deficit/Hyperactivity Disorder core symptoms: Meta-
analysis of five atomoxetine trials. Child Adolesc Psychiatry Ment Health
2010, 4:30.
32. Sonuga-Barke EJ, Swanson JM, Coghill D, DeCory HH, Hatch SJ: Efficacy of
two once-daily methylphenidate formulations compared across dose
levels at different times of the day: preliminary indications from a
secondary analysis of the COMACS study data. BMC Psychiatry 2004, 4:28.
33. Chou W-J, Chou M-C, Tzang R-F, Hsu Y-C, Gau SS-F, Chen S-J, Wu Y-Y,
Huang Y-F, Liang H-Y, Cheng H: Better efficacy for the osmotic release
oral system methylphenidate among poor adherents to immediate-
release methylphenidate in the three ADHD subtypes. Psych Clin Neurosci
2009, 63:167-175.
34. Kim Y, Shin M-S, Kim J-W, Yoo H-J, Cho S-C, Kim B-N: Neurocognitive
effects of switching from methylphenidate-IR to OROS-methylphenidate
in children with ADHD. Hum Psychopharmacol Clin Exp 2009, 24:95-102.
35. Barbaresi WJ, Katusic SK, Colligan RC, Weaver AL, Jacobsen SJ: Modifiers of
long-term school outcomes for children with attention-deficit/
hyperactivity disorder: does treatment with stimulant medication make
a difference? Results from a population-based study. J Dev Behav Pediatr
2007, 28(4):274-287.
36. Biederman J, Monuteaux MC, Spencer T, Wilens TE, Faraone SV: Do
stimulants protect against psychiatric disorders in youth with ADHD? A
10-year follow-up study. Pediatrics 2009, 124(1):71-78.
37. van den Ban E, Souverein PC, Swaab H, van Engeland H, Egberts TC,
Heerdink ER: Less discontinuation of ADHD drug use since the
availability of long-acting ADHD medication in children, adolescents and
adults under the age of 45 years in the Netherlands. Atten Defic Hyperact
Disord 2010, 2:213-220, Epub Nov 30, 2010.
doi:10.1186/1753-2000-5-26
Cite this article as: Berek et al.: Improved functionality, health related
quality of life and decreased burden of disease in patients with ADHD
treated with OROS
®® MPH: is treatment response different between
children and adolescents? Child and Adolescent Psychiatry and Mental
Health 2011 5:26.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Berek et al. Child and Adolescent Psychiatry and Mental Health 2011, 5:26
http://www.capmh.com/content/5/1/26
Page 13 of 13